PNC-27 vs PNC-28: What's the Difference?

PNC-27 and PNC-28 are both synthetic peptides built from the p53 tumor suppressor protein, and the central difference is length: PNC-27 carries the p53 12–26 sequence, while PNC-28 carries a shortened p53 17–26 sequence. Each one is fused to penetratin, a cell-penetrating carrier that helps the peptide cross cell membranes. In laboratory studies both bind HDM-2 and can trigger rapid membrane pore formation in cancer cells, but neither peptide is FDA-approved for human use.

What Is PNC-27 and What Is PNC-28?

Anyone searching for what is pnc-27 is really looking at a molecule with two distinct parts. One part copies the region of p53 that binds HDM-2, a protein also written as MDM2. The other part is a membrane-translocating sequence borrowed from the Antennapedia homeodomain.

PNC-28 uses the same two-part architecture with a shorter p53 fragment. Researchers designed the pnc-28 peptide to test whether a trimmed HDM-2 binding domain could preserve the cancer-cell-killing behavior of the longer molecule while using fewer amino acids.

The names are frequently written in reverse order, and searches for "pnc-28 vs pnc-27" point to the same comparison. Both compounds are supplied as lyophilized research powders and are handled in broadly similar ways in a laboratory setting.

PNC-27 vs PNC-28 at a Glance

Feature	PNC-27	PNC-28
p53-derived segment	Residues 12–26	Residues 17–26
Carrier sequence	Penetratin (membrane-translocating)	Penetratin (membrane-translocating)
Approximate length	About 32 amino acids	About 28 amino acids
Primary binding target	HDM-2	HDM-2
Proposed mechanism	HDM-2 binding and membrane pore formation	HDM-2 binding and membrane pore formation
Most-studied lab models	Breast, colon, melanoma, and leukemia cell lines	Pancreatic, colon, and breast cancer lines
Human clinical trials	None published	None published
Regulatory status in the US	Research chemical only	Research chemical only

How These Peptides Are Thought to Work

Step 1: Binding HDM-2

HDM-2 normally puts a brake on p53. Many cancer cells overproduce HDM-2, which helps them avoid p53-driven cell death. Both PNC-27 and PNC-28 are designed to dock onto HDM-2 using the p53-derived portion of the peptide.

Step 2: Membrane pore formation

After binding HDM-2, the peptide is reported to insert into the cancer cell membrane and form pores. That disruption produces necrosis rather than the slower, more orderly process of apoptosis, and in cell-culture experiments it has been observed within roughly 30 to 60 minutes.

Step 3: Selectivity in culture

Because the mechanism depends on HDM-2, cells with low HDM-2 expression are often less affected in lab assays. Normal human cells have generally shown limited damage in these experiments, although selectivity in a petri dish does not guarantee safety in a living organism.

What the Published Research Shows

• PNC-27 has been studied in breast, colon, melanoma, and leukemia cell lines, where it produced rapid cancer cell necrosis in vitro.
• PNC-28 has been studied most often in pancreatic cancer models, including PANC-1 and related lines, as well as in colon and breast cancer cells.
• Some reports describe activity in mouse xenograft models, but the animal numbers are small and the work is exploratory.
• No human clinical trials for either peptide have been published, so human dosing, safety, and effectiveness remain unknown.

Head-to-head comparisons are limited. Where both peptides have been tested side by side, they have shown similar HDM-2 binding and comparable cancer cell killing, with some pancreatic cancer studies suggesting PNC-28 stays active at similar or lower concentrations.

PNC-27 is generally the more frequently cited compound in the literature, which is one reason it appears in more vendor listings and discussion threads. Citation frequency, however, is not evidence of clinical effectiveness.

Safety, Legal Status, and Sourcing

Neither PNC-27 nor PNC-28 is approved by the FDA for human or veterinary use. Both are sold as research-grade chemicals, meaning they are not manufactured under pharmaceutical quality standards and are not intended for injection or ingestion.

If you encounter a pnc-27 protocol described online, treat it as unverified. No validated human protocol exists, and no clinical trial has established a safe dose, schedule, or route of administration. A licensed healthcare professional should be part of any conversation about experimental peptides.

Sourcing matters more than marketing copy. Searching for pnc-27 peptide sciences typically surfaces vendor pages, but the more useful question is whether a supplier provides a third-party certificate of analysis with HPLC purity data and mass spectrometry confirmation. Purity claims below 95 percent are common in cheap listings and can indicate truncated sequences or residual solvents.

Online pnc-27 reviews are almost entirely anecdotal and cannot be independently verified. They should not be treated as evidence of safety or effectiveness.

Handling and Reconstitution

Both peptides ship as lyophilized powder and are typically stored at -20 °C, protected from light. When choosing a diluent, the decision between reconstitution solution vs bacteriostatic water for peptides usually comes down to whether a vial will be used repeatedly. Bacteriostatic water contains benzyl alcohol, which slows microbial growth in multi-use vials, while plain sterile water is often preferred for single-use aliquots and for assays where benzyl alcohol could interfere.

The Bottom Line

PNC-27 and PNC-28 differ mainly in the length of their p53-derived segment, with PNC-27 carrying residues 12–26 and PNC-28 carrying residues 17–26. Both are HDM-2-targeting research peptides with similar proposed mechanisms and no human clinical data. Neither is FDA-approved, and decisions about experimental compounds belong with a licensed healthcare professional.

COMMON QUESTIONS

Frequently Asked Questions

Is PNC-27 the same as PNC-28?

No. Both peptides share a penetratin carrier and target HDM-2, but PNC-27 carries the p53 12–26 fragment while PNC-28 uses the shorter p53 17–26 fragment. That makes PNC-28 roughly 28 amino acids long versus about 32 for PNC-27.

Is PNC-27 FDA-approved or available for human use?

No. Neither PNC-27 nor PNC-28 is FDA-approved for human use in the United States. Both are sold as research chemicals for laboratory study only, and no human clinical trials have been published for either peptide.

Which is stronger, PNC-28 or PNC-27?

There is no definitive head-to-head human data, so no reliable potency ranking exists. In cell-culture studies both show similar HDM-2 binding and rapid cancer cell necrosis, and some pancreatic cancer reports suggest PNC-28 remains active at similar or lower concentrations.